Pfiz­er has agreed to pay $345 mil­lion as part of a set­tle­ment re­lat­ed to a 5-year-old law­suit over the com­pa­ny’s price hikes on the life­sav­ing EpiPen.

Plain­tiffs across the coun­try raised con­cerns over the price of the au­toin­jec­tor 2-pack, which they said spiked from about $100 in 2007 to $608 in 2016 — an in­crease of over 600%.

“Were the price in­creas­es at­trib­ut­able to mar­ket con­di­tions, in­creas­es in man­u­fac­tur­ing costs, or short­ages in the sup­ply of ep­i­neph­rine? Ab­solute­ly not. They were dri­ven sole­ly by un­ac­count­able ex­ec­u­tives and com­pa­nies who sought to prof­it off of hu­man mis­ery and fear,” the con­sol­i­dat­ed class ac­tion com­plaint from 2017 al­leged.

The com­plaint al­so al­leged that Pfiz­er vi­o­lat­ed cer­tain state an­titrust and fed­er­al rack­e­teer­ing laws, harm­ing com­pe­ti­tion and caus­ing con­sumers to over­pay for their EpiPens. And the court not­ed that of the $1 bil­lion that for­mer My­lan CEO Heather Bresch told Con­gress her com­pa­ny had in­vest­ed to en­hance the EpiPen and make it more avail­able, $879 mil­lion was spent on mar­ket­ing and sell­ing the EpiPen.

In an­nounc­ing the set­tle­ment, how­ev­er, Pfiz­er, which man­u­fac­tures the EpiPens, de­nied that it has en­gaged in any wrong­do­ing, de­nied any li­a­bil­i­ty for the claims and de­nied that plain­tiffs suf­fered any in­juries or dam­ages.

And while the court dis­missed many of the claims against My­lan in this suit last month, the com­pa­ny in 2017 agreed to pay $465 mil­lion to re­solve US Jus­tice De­part­ment claims that it know­ing­ly mis­clas­si­fied EpiPen as a gener­ic drug to avoid pay­ing re­bates.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended nine drugs for approval this week while also giving thumbs up for six expanded indications, including Novo Nordisk’s approved obesity medication Wegovy for younger people. Wegovy is already approved as an obesity treatment in the EU for adults, and the new indication would allow prescriptions for adolescents aged 12 and older.

RNA biotech GreenLight Biosciences has been handed an offer for potential acquisition.

GreenLight said in a release that it has received a non-binding “indication of interest” from Fall Line Endurance Fund to acquire GreenLight’s capital stock for $0.60 per share in cash. The release said any potential agreement between the two parties would depend on certain conditions.

Through a special committee, the biotech will evaluate the offer but added there’s no certainty a deal will go forward. GreenLight will also not make any more announcements until a deal comes through or “otherwise determines” a statement is necessary.

The German life science group Sartorius will be picking up French contract manufacturer Polyplus for the price of €2.4 billion, or $2.6 billion.

On Friday, Sartorius announced the acquisition through its French subgroup, Sartorius Stedim Biotech, which will be acquiring Polyplus from private investors ARCHIMED and WP GG Holdings IV. Polyplus has 270 employees and produces materials and components that go into making viral vectors that are used in cell and gene therapies. This includes DNA/RNA reagents as well as plasmid DNA. Polyplus has locations in France, Belgium, China and the US.